415 related articles for article (PubMed ID: 12183429)
21. PAX3 and PAX7 exhibit conserved cis-acting transcription repression domains and utilize a common gain of function mechanism in alveolar rhabdomyosarcoma.
Bennicelli JL; Advani S; Schäfer BW; Barr FG
Oncogene; 1999 Jul; 18(30):4348-56. PubMed ID: 10439042
[TBL] [Abstract][Full Text] [Related]
22. Pax3-fkhr and pax7-fkhr fusion genes impact outcome of alveolar rhabdomyosarcoma in children.
Kazanowska B; Reich A; Stegmaier S; Békássy AN; Leuschner I; Chybicka A; Koscielniak E
Fetal Pediatr Pathol; 2007; 26(1):17-31. PubMed ID: 17613043
[TBL] [Abstract][Full Text] [Related]
23. Inducible short-term and stable long-term cell culture systems reveal that the PAX3-FKHR fusion oncoprotein regulates CXCR4, PAX3, and PAX7 expression.
Tomescu O; Xia SJ; Strezlecki D; Bennicelli JL; Ginsberg J; Pawel B; Barr FG
Lab Invest; 2004 Aug; 84(8):1060-70. PubMed ID: 15184910
[TBL] [Abstract][Full Text] [Related]
24. Pax3:Fkhr interferes with embryonic Pax3 and Pax7 function: implications for alveolar rhabdomyosarcoma cell of origin.
Keller C; Hansen MS; Coffin CM; Capecchi MR
Genes Dev; 2004 Nov; 18(21):2608-13. PubMed ID: 15520281
[TBL] [Abstract][Full Text] [Related]
25. Investigation of PAX3/7-FKHR fusion genes and IGF2 gene expression in rhabdomyosarcoma tumors.
de Souza RR; Oliveira ID; Caran EM; Alves MT; Abib S; Toledo SR
Growth Horm IGF Res; 2012 Dec; 22(6):245-9. PubMed ID: 23079386
[TBL] [Abstract][Full Text] [Related]
26. Detection and clinical significance of bone marrow involvement in patients with rhabdomyosarcoma.
Krsková L; Mrhalová M; Hilská I; Sumerauer D; Drahokoupilová E; Múdry P; Kodet R
Virchows Arch; 2010 May; 456(5):463-72. PubMed ID: 20405298
[TBL] [Abstract][Full Text] [Related]
27. PAX3/forkhead homolog in rhabdomyosarcoma oncoprotein activates glucose transporter 4 gene expression in vivo and in vitro.
Armoni M; Quon MJ; Maor G; Avigad S; Shapiro DN; Harel C; Esposito D; Goshen Y; Yaniv I; Karnieli E
J Clin Endocrinol Metab; 2002 Nov; 87(11):5312-24. PubMed ID: 12414908
[TBL] [Abstract][Full Text] [Related]
28. The alveolar rhabdomyosarcoma PAX3/FKHR fusion protein is a transcriptional activator.
Sublett JE; Jeon IS; Shapiro DN
Oncogene; 1995 Aug; 11(3):545-52. PubMed ID: 7630639
[TBL] [Abstract][Full Text] [Related]
29. The PAX3-FKHR fusion protein created by the t(2;13) translocation in alveolar rhabdomyosarcomas is a more potent transcriptional activator than PAX3.
Fredericks WJ; Galili N; Mukhopadhyay S; Rovera G; Bennicelli J; Barr FG; Rauscher FJ
Mol Cell Biol; 1995 Mar; 15(3):1522-35. PubMed ID: 7862145
[TBL] [Abstract][Full Text] [Related]
30. Fusion of PAX7 to FKHR by the variant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma.
Davis RJ; D'Cruz CM; Lovell MA; Biegel JA; Barr FG
Cancer Res; 1994 Jun; 54(11):2869-72. PubMed ID: 8187070
[TBL] [Abstract][Full Text] [Related]
31. Normal and rearranged PAX3 expression in human rhabdomyosarcoma.
Frascella E; Toffolatti L; Rosolen A
Cancer Genet Cytogenet; 1998 Apr; 102(2):104-9. PubMed ID: 9546061
[TBL] [Abstract][Full Text] [Related]
32. PAX--FKHR fusion genes and AChR-gamma in Chinese patients with rhabdomyosarcoma: diagnosis using formalin-fixed archival tissues.
Chang B; Pang LJ; Qi Y; Liu CX; Cao Y; Li HA; Hu WH; Jiang JF; Zhang WJ; Li F
Int J Surg Pathol; 2009 Feb; 17(1):6-15. PubMed ID: 18988640
[TBL] [Abstract][Full Text] [Related]
33. Identification of a PAX-FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas.
Davicioni E; Finckenstein FG; Shahbazian V; Buckley JD; Triche TJ; Anderson MJ
Cancer Res; 2006 Jul; 66(14):6936-46. PubMed ID: 16849537
[TBL] [Abstract][Full Text] [Related]
34. Analysis of genetic events that modulate the oncogenic and growth suppressive activities of the PAX3-FKHR fusion oncoprotein.
Xia SJ; Rajput P; Strzelecki DM; Barr FG
Lab Invest; 2007 Apr; 87(4):318-25. PubMed ID: 17297479
[TBL] [Abstract][Full Text] [Related]
35. Wild type PAX3 protein and the PAX3-FKHR fusion protein of alveolar rhabdomyosarcoma contain potent, structurally distinct transcriptional activation domains.
Bennicelli JL; Fredericks WJ; Wilson RB; Rauscher FJ; Barr FG
Oncogene; 1995 Jul; 11(1):119-30. PubMed ID: 7624119
[TBL] [Abstract][Full Text] [Related]
36. A Drosophila model of the rhabdomyosarcoma initiator PAX7-FKHR.
Galindo RL; Allport JA; Olson EN
Proc Natl Acad Sci U S A; 2006 Sep; 103(36):13439-44. PubMed ID: 16938866
[TBL] [Abstract][Full Text] [Related]
37. Genomic and clinical analysis of fusion gene amplification in rhabdomyosarcoma: a report from the Children's Oncology Group.
Duan F; Smith LM; Gustafson DM; Zhang C; Dunlevy MJ; Gastier-Foster JM; Barr FG
Genes Chromosomes Cancer; 2012 Jul; 51(7):662-74. PubMed ID: 22447499
[TBL] [Abstract][Full Text] [Related]
38. Structural analysis of PAX3 genomic rearrangements in alveolar rhabdomyosarcoma.
Barr FG; Nauta LE; Hollows JC
Cancer Genet Cytogenet; 1998 Apr; 102(1):32-9. PubMed ID: 9530337
[TBL] [Abstract][Full Text] [Related]
39. Mechanism for transcriptional gain of function resulting from chromosomal translocation in alveolar rhabdomyosarcoma.
Bennicelli JL; Edwards RH; Barr FG
Proc Natl Acad Sci U S A; 1996 May; 93(11):5455-9. PubMed ID: 8643596
[TBL] [Abstract][Full Text] [Related]
40. The role of chimeric paired box transcription factors in the pathogenesis of pediatric rhabdomysarcoma.
Barr FG
Cancer Res; 1999 Apr; 59(7 Suppl):1711s-1715s. PubMed ID: 10197585
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]